Verve Therapeutics price target raised to $32 from $29 at Canaccord

Canaccord raised the firm’s price target on Verve Therapeutics (VERV) to $32 from $29 and keeps a Buy rating on the shares. The firm said its 3Q24 earnings report was positive, with notable clinical progress made in both base editing programs.